• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home The Classics Cardiology Classics

The DAPA-HF trial: Dapagliflozin in patients with heart failure [Classics Series]

byDeepti Shroff Karhade
June 10, 2022
in Cardiology Classics, The Classics
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

This study summary is an excerpt from the book 2 Minute Medicine’s The Classics in Medicine: Summaries of the Landmark Trials

1. This study found that patients with heart failure with reduced ejection fraction (HFrEF) who received dapagliflozin had lower rates of composite cardiovascular death and worsening heart failure (16.3%) compared to controls (21.1%).

2. Presence or absence of diabetes had no significant impact on the outcomes in either group.

Original Date of Publication: November 2019

Study Rundown: The Dapagliflozin and Prevention of Adverse Outcomes in Heart Failure (DAPA-HF) trial evaluated the cardioprotective effects of the sodium–glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin in patents with HFrEF. Composite cardiovascular death and worsening heart failure was significantly lower in those taking dapagliflozin as compared to placebo. Although SGLT2 inhibitors are typically used in diabetic patients, the presence or absence of diabetes did not alter outcomes in either group. The secondary composite outcome of cardiovascular death and hospitalizations for heart failure was also significantly reduced in the dapagliflozin group. The main limitation of the DAPA-HF trail was limited diversity in the study population, possibly impacting generalizability of the results. The DAPA-HF trial was the first study to demonstrate that in HFrEF patients both with and without diabetes, dapagliflozin reduces progression of heart failure, associated hospitalizations, and risk of cardiovascular death.

Click to read the study in NEJM

In-Depth [randomized control trial]: The DAPA-HF trial was conducted on a group of HFrEF patients (n = 4744) who were randomized into either a dapagliflozin group (n = 2373) or placebo (n = 2371) for a median duration of follow-up of 18.2 months. All trial outcomes were adjudicated by a blinded clinical-events committee. The primary composite endpoint of cardiovascular death and worsening heart failure characterized by hospitalization or urgent primary care visit resulting in intravenous therapy was significantly lower in the dapagliflozin group (16.3%) than the placebo group (21.2%) (HR 0.74; 95%CI 0.65-0.85). The dapagliflozin group also had a significantly reduced rate of the composite outcome of cardiovascular death and hospitalization due to heart failure (HR 0.75; 95%CI 0.65-0.85). Both groups were matched at screening for type 2 diabetes (42%) and diabetes status did not have any impact on the primary or the secondary composite outcomes.

RELATED REPORTS

SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes

#VisualAbstract: Treatment with empagliflozin reduced progression of chronic kidney disease

Dapagliflozin associated with reduction in cardiovascular mortality due to lower rates of death from heart failure and sudden death – Pooled analysis of DAPA-HF and DELIVER

McMurray JJV, Solomon SD, Inzucchi SE, Køber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. New England Journal of Medicine. 2019 Nov 21;381(21):1995–2008.

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: dapagliflozinHFrEF (heart failure with reduced ejection fraction)SGLT-2 inhibitors
Previous Post

Interventions prompted by primary care providers increases physical activity

Next Post

#VisualAbstract: Whole-genome sequencing changes clinical management in significant number of critically ill infants

RelatedReports

Tenofovir disoprovil fumarate HIV prophylaxis linked with minimal kidney impact
Chronic Disease

SGLT2 inhibitors reduce the risk of kidney disease in patients with and without diabetes

November 30, 2022
#VisualAbstract: Treatment with empagliflozin reduced progression of chronic kidney disease
StudyGraphics

#VisualAbstract: Treatment with empagliflozin reduced progression of chronic kidney disease

November 11, 2022
Radiation dose associated with increased heart disease in Hodgkin lymphoma survivors
Cardiology

Dapagliflozin associated with reduction in cardiovascular mortality due to lower rates of death from heart failure and sudden death – Pooled analysis of DAPA-HF and DELIVER

October 16, 2022
#VisualAbstract: Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction
StudyGraphics

#VisualAbstract: Dapagliflozin slows disease progression in patients with heart failure with preserved ejection fraction

October 5, 2022
Next Post
#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication

#VisualAbstract: Whole-genome sequencing changes clinical management in significant number of critically ill infants

#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication

#VisualAbstract: Only one quarter of benzodiazepine prescriptions in youth are for approved indication

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

#VisualAbstract Ponatinib with FLAG-IDA is a feasible and active treatment strategy in patients with blast-phase chronic myeloid leukaemia

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Cystatin C-based equation without race or sex improves accuracy of GFR estimation
  • #VisualAbstract: Aldosterone synthase inhibition reduced systolic blood pressure in patients with treatment-resistant hypertension
  • High-dose exercise therapy is not superior to low-dose exercise therapy for knee osteoarthritis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options